Adjust Text Size:change font sizechange font sizechange font sizechange font sizechange font sizechange font size

Featured Research

Can we predict who is at risk of facing cognitive issues in PD and address them earlier? These are the questions being pursued by Dr. Goldman of the PDF Research Center at Rush University Medical Center.

Learn More

PDF Grant Programs

Are you interested in furthering Parkinson's science? View PDF's open grant programs.

Learn More


Intramuscular injection of ?-synuclein induces CNS ?-synuclein pathology and a rapid-onset motor phenotype in transgenic mice.

PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research. 

Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members?  Please browse PDF's educational materials and programs - which are all available electronically or in print.  Order for yourself, a loved one or in bulk for your patients or support group.

Proc Natl Acad Sci U S A 2014 Jul; 111(29):10732-7

Authors: Amanda N Sacino, Mieu Brooks, Michael A Thomas, Alex B McKinney, Sooyeon Lee, Robert W Regenhardt, Nicholas H McGarvey, Jacob I Ayers, Lucia Notterpek, David R Borchelt, Todd E Golde, Benoit I Giasson

It has been hypothesized that ?-synuclein (?S) misfolding may begin in peripheral nerves and spread to the central nervous system (CNS), leading to Parkinson disease and related disorders. Although recent data suggest that ?S pathology can spread within the mouse brain, there is no direct evidence for spread of disease from a peripheral site. In the present study, we show that hind limb intramuscular (IM) injection of ?S can induce pathology in the CNS in the human Ala53Thr (M83) and wild-type (M20) ?S transgenic (Tg) mouse models. Within 2-3 mo after IM injection in ?S homozygous M83 Tg mice and 3-4 mo for hemizygous M83 Tg mice, these animals developed a rapid, synchronized, and predictable induction of widespread CNS ?S inclusion pathology, accompanied by astrogliosis, microgliosis, and debilitating motor impairments. In M20 Tg mice, starting at 4 mo after IM injection, we observed ?S inclusion pathology in the spinal cord, but motor function remained intact. Transection of the sciatic nerve in the M83 Tg mice significantly delayed the appearance of CNS pathology and motor symptoms, demonstrating the involvement of retrograde transport in inducing ?S CNS inclusion pathology. Outside of scrapie-mediated prion disease, to our knowledge, this findiing is the first evidence that an entire neurodegenerative proteinopathy associated with a robust, lethal motor phenotype can be initiated by peripheral inoculation with a pathogenic protein. Furthermore, this facile, synchronized rapid-onset model of ?-synucleinopathy will be highly valuable in testing disease-modifying therapies and dissecting the mechanism(s) that drive ?S-induced neurodegeneration.

PMID: 25002524 [PubMed - as supplied by publisher]

See More

Back to PubMed Articles